Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

2004 • 4,872 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

The immune contexture in human tumours: impact on clinical outcome

2012 • 4,275 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 • 4,054 citations

Innate and adaptive immune cells in the tumor microenvironment

2013 • 3,541 citations

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

2002 • 2,879 citations

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

2003 • 2,177 citations

CTLA-4 can function as a negative regulator of T cell activation

1994 • 2,107 citations

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

2013 • 1,513 citations

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

2011 • 1,452 citations

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

2013 • 1,310 citations

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

2009 • 1,000 citations

Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity

2005 • 972 citations

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

1996 • 917 citations

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

2009 • 825 citations

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

2004 • 748 citations

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

2013 • 629 citations

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

2013 • 585 citations

Reversal of the TCR Stop Signal by CTLA-4

2006 • 584 citations

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

2011 • 583 citations

Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

2011 • 529 citations

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

2010 • 499 citations

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

2004 • 476 citations

Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancy

2001 • 425 citations

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

2004 • 368 citations

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

2013 • 289 citations

Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

2009 • 281 citations

Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy

2013 • 275 citations

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

2017 • 270 citations

Gene Signature in Melanoma Associated With Clinical Activity

2010 • 247 citations

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

2010 • 240 citations

Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

2008 • 219 citations

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells

2013 • 168 citations

Transient T cell depletion causes regression of melanoma metastases

2008 • 153 citations

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

2013 • 151 citations

Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer

2007 • 131 citations

The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell–expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches

2005 • 110 citations

Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

2012 • 108 citations

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

2013 • 97 citations

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

2012 • 95 citations

Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma

2008 • 89 citations

Immunomodulatory Cytokines as Therapeutic Agents for Melanoma

2011 • 74 citations

Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood

2008 • 73 citations

Rational combinations of immunotherapeutics that target discrete pathways

2013 • 65 citations

Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor‐specific CD8⁺ T cells

2008 • 53 citations

Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A

2001 • 53 citations

Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation

2012 • 45 citations

Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.

2013 • 38 citations

Combination antibody‐based cancer immunotherapy

2007 • 20 citations